Behind the headlines: The effects of COVID-19 on people with lymphoma
Our Medical Advisory Panel respond to a recent report in The Independent.
News
All news
Read the latest news and views from Lymphoma Action.
Use the drop down filter to find the most relevant news for you.
NICE approves new treatment for DLBCL
The National Institutes for Health and Care Excellence (NICE) has approved polatuzumab vedotin for use on the NHS in people with diffuse large B-cell lymphoma (DLBCL).
NICE consultation on chlormethine gel for skin lymphoma
Have your say on chlormethine gel for mycosis fungoides - consultation runs until 26 August.
NICE consultation on mogamulizumab for skin lymphoma
Have your say on mogamulizumab for mycosis fungoides and Sézary syndrome - CLOSES TODAY (19 August)
Lymphoma Action welcomes new Trustee
We are pleased to welcome James Cray as a Trustee of Lymphoma Action.
New treatment approval for CLL
The European Medicines Agency has approved acalabrutinib for chronic lymphocytic leukaemia (CLL).
BSH publish new guidelines on follicular lymphoma
Updated guidelines for the diagnosis and treatment of people with follicular lymphoma.
Round the grounds cyclists ride for Lymphoma Action
Hugh and his fellow cyclists covered 62-miles and stopped at all 12 London football league grounds to support our work.
Thank you - Emergency Appeal 2020
We are so grateful to everyone who has already donated to our 2020 Emergency Appeal.
Our team have recorded a special thank you for this vital support at such a challenging time.
Encouraging results for new treatments in DLBCL
Tafasitamab plus lenalidomide show promise for people with relapsed or refractory DLBCL who are not suitable for a stem cell transplant.